LifeMD扩大诺和诺德合作范围，以每月499美元的价格提供Ozempic访问

Ozempic® is now available at this reduced price to eligible self-pay LifeMD patients

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care, today announced an additional offering through its collaboration with Novo Nordisk that provides access to Ozempic® (semaglutide), a GLP-1 RA for patients with type 2 diabetes, at $499 per month. Through LifeMD's integration with NovoCare® Pharmacy, eligible self-pay and uninsured patients, as well as insured patients whose plans do not cover GLP-1 therapies, now have direct access to all FDA-approved dose strengths of Ozempic® within LifeMD's end-to-end virtual care platform.